Achieve Life Sciences nabs $124M; Pierre Fabre buys pan-RAF program from Kinnate

Plus, news about Tar­sus Phar­ma­ceu­ti­cals, Hu­ma­cyte, Stem­cell Tech­nolo­gies and SQZ Biotech­nolo­gies:

Achieve Life Sci­ences rais­es $124M, de­tails plans for NDA: The com­pa­ny plans to sub­mit its smok­ing ces­sa­tion treat­ment to the FDA in the first half of 2025. It brought in mon­ey from Pro­pel Bio Part­ners, Nan­ta­ha­la Cap­i­tal and Sophar­ma, among oth­ers. Per the di­rect of­fer­ing and pri­vate place­ment, Achieve gets $60 mil­lion up­front and $64.2 mil­lion up­on cer­tain mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.